With reference to monoclonal antibodies, often mentioned in news, consider the following statements: I. They are man-made proteins. II. They stimulate immunological function due to their ability to bind to specific antigens. III. They are used in treating viral infections like that of Nipah virus. Which of the statements given above are correct?
Contents23
- AI and II only
- BII and III only
- CI and III only
- DI, II and III
Show answer
Answer: (D) I, II and III
Monoclonal antibodies (mAbs) are frequently in the news due to their growing role in treating diseases.
Let's check each statement:
(I) 'They are man-made proteins' — CORRECT.
Monoclonal antibodies are produced in laboratories.
Scientists first identify an antibody that binds to a specific target, then mass-produce identical copies (clones) of that single antibody using cell cultures.
The word 'monoclonal' means 'from a single clone.' ✓
(II) 'They stimulate immunological function due to their ability to bind to specific antigens' — CORRECT.
Monoclonal antibodies work by binding precisely to specific antigens (proteins on the surface of cells, viruses, or other targets).
This binding can mark diseased cells for destruction by the immune system, block harmful signals, or deliver drugs directly to target cells. ✓
(III) 'They are used in treating viral infections like Nipah virus' — CORRECT.
Monoclonal antibody m102.4 has been used as an experimental treatment for Nipah virus infections.
During outbreaks in India (especially in Kerala), monoclonal antibody therapy has been considered as a treatment option.
mAbs are also used against other viruses — for example, Regeneron and Eli Lilly developed mAbs for COVID-19. ✓
All three statements are correct.
Answer is (d).
Monoclonal antibodies became prominent news during COVID-19 pandemic when companies like Regeneron and Eli Lilly developed mAb treatments, and they continue to be used for emerging viral threats like Nipah outbreaks in Kerala.
The question tests understanding of both the technical mechanism of mAbs (laboratory production, antigen-binding specificity) and their practical medical applications in viral disease treatment.
Monoclonal Antibodies
Science And Technology monoclonal antibodies man-made proteins bind to specific antigens
Monoclonal Antibodies: Production, Mechanism & Medical Applications
mAbs are laboratory-produced antibodies from a single clone of immune cells
They bind to specific antigens to mark cells for immune destruction or block harmful signals
Used for cancer, autoimmune diseases, and viral infections including Nipah virus
Monoclonal means 'from a single clone' - all antibodies are identical
What Are mAbs
Monoclonal antibodies (mAbs) are man-made proteins produced in laboratories to mimic natural antibodies. The term 'monoclonal' means 'from a single clone' - scientists take one antibody-producing cell and create millions of identical copies.
Production Process
%%{init: {"flowchart": {"wrappingWidth": 460}}}%%
flowchart TD
s1["`**Target Identification**
Scientists identify specific **antigen** on diseased cells or pathogens`"]
s2["`**Antibody Selection**
Find natural antibody that binds strongly to the target antigen`"]
s3["`**Cell Fusion**
Fuse antibody-producing B-cells with immortal myeloma cells`"]
s4["`**Clone Selection**
Select single clone producing the desired antibody`"]
s5["`**Mass Production**
Grow millions of identical cells in laboratory cultures`"]
s1 --> s2
s2 --> s3
s3 --> s4
s4 --> s5Medical Applications
Disease Type | Examples | How mAbs Work | Specific mAb |
|---|---|---|---|
Cancer | Breast cancer, Lymphoma | Mark cancer cells for immune destruction | Trastuzumab, Rituximab |
Viral Infections | COVID-19, Nipah virus | Neutralize virus or block entry into cells | m102.4 for Nipah, Regeneron for COVID |
Autoimmune | Rheumatoid arthritis, Psoriasis | Block inflammatory signals | Adalimumab, Infliximab |
Transplant | Organ rejection | Suppress immune response | Basiliximab, Daclizumab |
Mechanism of Action
Specific binding: Each mAb targets one specific antigen with lock-and-key precision
Immune activation: Binding marks target cells for destruction by natural killer cells and macrophages
Signal blocking: Can prevent harmful cellular signals or block virus entry into healthy cells
Drug delivery: Can carry chemotherapy drugs directly to cancer cells, reducing side effects
Nipah Virus Context
m102.4 monoclonal antibody has been used experimentally for Nipah virus treatment. During Kerala outbreaks, this therapy was considered because Nipah has high mortality and no proven treatment. mAbs work by neutralizing the virus before it enters human cells.
Trap: Confusing monoclonal with polyclonal antibodies - polyclonal come from multiple cell clones
Trap: Thinking mAbs suppress immunity - they actually enhance targeted immune responses
Trap: All three statements in this question are correct - students often miss statement III about viral infections
Nipah Virus
Science And Technology Nipah virus viral infections
Nipah Virus: Transmission, Outbreaks & Treatment Challenges
Zoonotic virus transmitted from fruit bats to humans, causing brain inflammation
Kerala outbreaks in 2018, 2019, 2021, 2023 - major public health concern in India
High mortality rate (40-75%) with no approved vaccine or specific treatment
Human-to-human transmission possible through respiratory droplets and body fluids
Disease Overview
Nipah virus (NiV) is a deadly zoonotic pathogen that causes severe brain inflammation (encephalitis). First identified in Malaysia in 1998, it has since caused multiple outbreaks across South and Southeast Asia.
Transmission Chain
%%{init: {"flowchart": {"wrappingWidth": 460}}}%%
flowchart TD
s1["`**Natural Reservoir**
**Fruit bats** (Pteropus species) carry virus without getting sick`"]
s2["`**Intermediate Hosts**
Pigs, horses, other mammals can get infected from bat saliva/urine`"]
s3["`**Environmental Contamination**
Bats contaminate **date palm sap**, fruits with saliva and urine`"]
s4["`**Human Infection**
Humans consume contaminated food or contact infected animals`"]
s5["`**Human Transmission**
**Person-to-person** spread through respiratory droplets and body fluids`"]
s1 --> s2
s2 --> s3
s3 --> s4
s4 --> s5Major Outbreaks in India
Year | Location | Cases | Deaths | Key Features |
|---|---|---|---|---|
2018 | Kozhikode, Kerala | 19 | 17 | First outbreak in India, high mortality |
2019 | Kochi, Kerala | 1 | 1 | Single case, rapid containment |
2021 | Kozhikode, Kerala | 1 | 1 | 12-year-old boy, contact tracing successful |
2023 | Kozhikode, Kerala | 6 | 2 | Family cluster, m102.4 antibody used |
Clinical Features
Initial symptoms: Fever, headache, muscle pain, vomiting - similar to flu
Neurological stage: Dizziness, drowsiness, altered consciousness, brain inflammation
Severe cases: Seizures, coma, respiratory distress leading to death
Incubation period: 4-14 days from exposure to symptom onset
Treatment Challenges
No approved vaccine or specific antiviral exists. Treatment is supportive care only. Monoclonal antibody m102.4 has been used experimentally in recent Kerala outbreaks with some success, but it's not yet approved for routine use.
Geographic Distribution
Source: Avian Flu Diary — Avian Flu Diary: A Brief History of the Nipah Virus · afludiary.blogspot.com
Trap: Confusing Nipah with Ebola - both are deadly but Nipah is primarily encephalitis, Ebola is hemorrhagic fever
Trap: Thinking Nipah spreads only through bats - human-to-human transmission is documented
Trap: UPSC often tests Kerala connection - know that multiple Nipah outbreaks occurred there
Antibodies vs Antigens
Science And Technology antigens immunological function
Antibodies vs Antigens: Key Differences & Immune Mechanism
Antigens are foreign substances that trigger immune response; antibodies are proteins that fight them
Lock-and-key binding: Each antibody binds to specific antigen with precise molecular recognition
B-cells produce antibodies after recognizing antigens presented by immune cells
Antibodies vs Antigens
Feature | Antibodies | Antigens |
|---|---|---|
Definition | Y-shaped proteins that fight foreign substances | Foreign substances that trigger immune response |
Origin | Produced by B-cells in immune system | Come from pathogens, toxins, foreign cells |
Function | Bind and neutralize specific threats | Trigger antibody production |
Structure | Immunoglobulin proteins (IgG, IgM, IgA, IgE, IgD) | Usually proteins on surface of pathogens |
Specificity | Each antibody targets one specific antigen | Each antigen can trigger multiple antibodies |
Location | Circulate in blood and lymph | On surface of viruses, bacteria, cancer cells |
Antigen-Antibody Response
%%{init: {"flowchart": {"wrappingWidth": 460}}}%%
flowchart TD
s1["`**Antigen Entry**
Foreign pathogen with surface **antigens** enters body`"]
s2["`**Recognition**
**Antigen-presenting cells** capture and display antigen fragments`"]
s3["`**B-cell Activation**
**B-cells** with matching receptors recognize specific antigen`"]
s4["`**Antibody Production**
Activated B-cells multiply and produce **specific antibodies**`"]
s5["`**Binding & Neutralization**
Antibodies bind to antigens, marking them for immune destruction`"]
s1 --> s2
s2 --> s3
s3 --> s4
s4 --> s5Types of Antigens
# Antigens
## **Pathogen Antigens**
- Viral proteins
- Bacterial surface proteins
- Fungal cell wall components
## **Self vs Non-Self**
- Blood group antigens
- Tissue compatibility antigens
- Cancer cell antigens
## **Environmental**
- Pollen proteins
- Food allergens
- Drug moleculesClinical Applications
Vaccine principle: Introduce harmless antigens to train immune system to recognize real pathogens
Blood typing: ABO antigens determine blood compatibility for transfusions
Autoimmune diseases: Immune system mistakenly targets body's own antigens
Cancer therapy: Target tumor-specific antigens with monoclonal antibodies
Trap: Thinking antibodies suppress immunity - they actually enhance targeted immune responses
Trap: Confusing which is which - Antigens are Anti-body Generators (remember this)
Trap: One antibody can bind multiple antigens - FALSE, each antibody is highly specific to one antigen
Biotechnology in Medicine
Science And Technology
Biotechnology Applications in Modern Medicine
Recombinant DNA technology produces human proteins like insulin in bacteria
Gene therapy treats diseases by introducing functional genes into patient cells
CAR-T therapy modifies patient's immune cells to fight cancer more effectively
Biosimilars are cheaper versions of expensive biologic drugs
Revolution in Medicine
Biotechnology has transformed medicine from small chemical drugs to large biological molecules. Modern treatments use living systems to produce complex proteins that cannot be synthesized chemically.
Major Biotechnology Products
Product Type | Examples | Production Method | Medical Use |
|---|---|---|---|
Recombinant Proteins | Insulin, Growth hormone | E. coli bacteria production | Diabetes, Growth disorders |
Monoclonal Antibodies | Trastuzumab, Rituximab | Hybridoma cell cultures | Cancer, Autoimmune diseases |
Vaccines | Hepatitis B, HPV | Yeast or insect cell expression | Disease prevention |
Gene Therapies | CAR-T, CRISPR treatments | Modified patient cells | Cancer, Genetic disorders |
Biosimilars | Generic biologics | Reverse-engineered production | Cost-effective treatment |
Biotechnology Branches
# Medical Biotechnology
## **Protein Engineering**
- Monoclonal antibodies
- Recombinant proteins
- Enzyme replacement therapy
## **Gene Technology**
- Gene therapy
- CRISPR editing
- RNA interference
## **Cell Therapy**
- Stem cell therapy
- CAR-T cells
- Tissue engineering
## **Diagnostics**
- PCR testing
- DNA sequencing
- Biomarker detectionIndian Context
Biocon: Leading Indian biopharmaceutical company producing insulin and monoclonal antibodies
Biosimilar hub: India is global leader in producing cheaper versions of expensive biologics
Gene therapy approvals: CDSCO approved CAR-T therapy trials in Indian hospitals
COVID-19 vaccines: Covaxin used biotechnology platform for indigenous vaccine development
Trap: Confusing biotechnology with nanotechnology - biotech uses living systems, nanotech uses tiny materials
Trap: Thinking all medicines are biotechnology products - traditional small molecule drugs are still chemistry-based
Trap: UPSC often asks about Indian biotech companies - know Biocon, Serum Institute